BloodHumansLeukemiaMyeloidAcutefms-Like Tyrosine Kinase 3
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Bogdan Popescu, Matthew F Jones, Madison Piao, Elaine Tran, Andrew Koh, Isabelle Lomeli, Cheryl A C Peretz, Natalia Murad, Sydney Abelson, Carolina Morales, Jose M Rivera, Alexa Rane Batingana, Jeevitha D'Souza, Yana Pikman, Michael L Cheng
Published: 202610.1182/blood.2025030558
Abstract
ABSTRACT: Aberrant activation of RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FMS-like tyrosine kinase-3 (FLT3)-mutant AML, the selection of clones harboring heterogeneous RAS mutat…
Preview only. Read the full abstract at the source